Antitumor effect of a newly synthesized celecoxib derivative encapsulated in liposome
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim B. | - |
dc.contributor.author | Shin D.H. | - |
dc.contributor.author | Kim H.D. | - |
dc.contributor.author | Kim J.-S. | - |
dc.date.available | 2021-02-22T10:56:13Z | - |
dc.date.issued | 2013-04 | - |
dc.identifier.issn | 2093-5552 | - |
dc.identifier.issn | 2093-6214 | - |
dc.identifier.uri | https://scholarworks.sookmyung.ac.kr/handle/2020.sw.sookmyung/6406 | - |
dc.description.abstract | A new cyclooxygenase-2 inhibitor (code: PCX-3) was synthesized as a sodium salt form of celecoxib, a non-steroidal anti-inflammatory drug (NSAID), and tested for its anticancer activity using human colon adenocarcinoma cells (HT-29) in vitro. Anti-proliferative effect of HT-29 cells by PCX-3 in DPPC/Chol liposomes was more effective than the free PCX-3 by 2-folds (IC30 = 125 μM vs. 227.5 μM). The same liposomal formulation of PCX-3 also showed a 2-fold increased effect than the free one both in DNA fragmentation and caspase activity of HT-29 cells at 19-743 μM and 37-371 μM ranges, respectively, suggesting apoptosis-based anti-proliferative effect. Down regulation of prostaglandin E2 level of HT-29 cells by the treatment of liposomal PCX-3 was more profound than its free form at 0.001-0.002 μM range. These data suggest that the liposomal formulation of this newly synthesized PCX-3 could be re-visited as a new anticancer or chemo-preventive agent in the future. © 2013 The Korean Society of Pharmaceutical Sciences and Technology. | - |
dc.format.extent | 6 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | 한국약제학회 | - |
dc.title | Antitumor effect of a newly synthesized celecoxib derivative encapsulated in liposome | - |
dc.type | Article | - |
dc.publisher.location | 미국 | - |
dc.identifier.doi | 10.1007/s40005-013-0057-4 | - |
dc.identifier.scopusid | 2-s2.0-84892990011 | - |
dc.identifier.bibliographicCitation | Journal of Pharmaceutical Investigation, v.43, no.2, pp 101 - 106 | - |
dc.citation.title | Journal of Pharmaceutical Investigation | - |
dc.citation.volume | 43 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 101 | - |
dc.citation.endPage | 106 | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART001761592 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.subject.keywordPlus | 3 (4, 5 dimethyl 2 thiazolyl) 2, 5 diphenyltetrazolium bromide | - |
dc.subject.keywordPlus | caspase 3 | - |
dc.subject.keywordPlus | caspase 7 | - |
dc.subject.keywordPlus | celecoxib derivative | - |
dc.subject.keywordPlus | cholesterol | - |
dc.subject.keywordPlus | cyclooxygenase 2 inhibitor | - |
dc.subject.keywordPlus | dipalmitoylphosphatidylcholine | - |
dc.subject.keywordPlus | liposome | - |
dc.subject.keywordPlus | messenger RNA | - |
dc.subject.keywordPlus | pcx 3 | - |
dc.subject.keywordPlus | prostaglandin E2 | - |
dc.subject.keywordPlus | unclassified drug | - |
dc.subject.keywordPlus | antineoplastic activity | - |
dc.subject.keywordPlus | antiproliferative activity | - |
dc.subject.keywordPlus | apoptosis | - |
dc.subject.keywordPlus | article | - |
dc.subject.keywordPlus | caspase assay | - |
dc.subject.keywordPlus | cell culture | - |
dc.subject.keywordPlus | colon adenocarcinoma | - |
dc.subject.keywordPlus | controlled study | - |
dc.subject.keywordPlus | DNA fragmentation | - |
dc.subject.keywordPlus | drug synthesis | - |
dc.subject.keywordPlus | human | - |
dc.subject.keywordPlus | human cell | - |
dc.subject.keywordPlus | liposomal delivery | - |
dc.subject.keywordPlus | MTT assay | - |
dc.subject.keywordPlus | priority journal | - |
dc.subject.keywordAuthor | Anticancer drugs | - |
dc.subject.keywordAuthor | Caspase | - |
dc.subject.keywordAuthor | Celecoxib | - |
dc.subject.keywordAuthor | COX-2 | - |
dc.subject.keywordAuthor | Liposomes | - |
dc.identifier.url | https://link.springer.com/article/10.1007%2Fs40005-013-0057-4 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
Sookmyung Women's University. Cheongpa-ro 47-gil 100 (Cheongpa-dong 2ga), Yongsan-gu, Seoul, 04310, Korea02-710-9127
Copyright©Sookmyung Women's University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.